Cargando…

CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML

Detalles Bibliográficos
Autores principales:	Satlsar, Esmaeil Shahabi, Mosleh, Mohammad, Mehrpouri, Mahdieh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702646/ https://www.ncbi.nlm.nih.gov/pubmed/32517420 http://dx.doi.org/10.4274/tjh.galenos.2020.2020.0110

Ejemplares similares

Comment: In Response to “CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML”
por: Gajendra, Smeeta
Publicado: (2020)

A Flow Cytometry Panel for Differential Diagnosis of Mantle Cell Lymphoma from Atypical B-Chronic Lymphocytic Leukaemia
por: Mehrpouri, Mahdieh, et al.
Publicado: (2023)

Co-culture of Platelets with Monocytes Induced M2 Macrophage Polarization and Formation of Foam Cells: Shedding Light on the Crucial Role of Platelets in Monocyte Differentiation
por: Mehrpouri, Mahdieh, et al.
Publicado: (2019)

SYK Regulates mTOR Signaling in AML
por: Carnevale, Julia, et al.
Publicado: (2013)

CD56, HLA‐DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3‐GLIS2 fusion transcript
por: Zangrando, Andrea, et al.
Publicado: (2021)

CD105 (Endoglin) as negative prognostic factor in AML
por: Kauer, Joseph, et al.
Publicado: (2019)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
por: Konopleva, Marina, et al.
Publicado: (2023)

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
por: Darici, Salihanur, et al.
Publicado: (2020)

Immediate early response 3 gene promotes aggressive progression and autophagy of AML by negatively regulating AKT/mTOR
por: Chen, Yimin, et al.
Publicado: (2023)

MicroRNA–mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients
por: Bhise, Neha S., et al.
Publicado: (2016)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

UCB HCT in FLT3+ AML
por: Ustun, Celalettin, et al.
Publicado: (2017)

Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022)

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation
por: Federzoni, Elena A., et al.
Publicado: (2014)

How mRNA is misspliced in acute myelogenous leukemia (AML)?
por: Mohamed, Aminetou Mint, et al.
Publicado: (2014)

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
por: Huber, Sandra, et al.
Publicado: (2023)

P1254: BASELINE HLA-DR-RESTRICTED NEOANTIGEN BURDEN OF AML BLASTS IMPACTS ON HLA-DR GENE EXPRESSION AT RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANT
por: Charrot, Sarah, et al.
Publicado: (2023)

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
por: Lindblad, O, et al.
Publicado: (2016)

Management of AML Beyond “3 + 7” in 2019
por: Canaani, Jonathan
Publicado: (2019)

Targeting mTOR for the treatment of AML. New agents and new directions
por: Altman, Jessica K., et al.
Publicado: (2011)

Pseudo Chediak Higashi-like inclusions in myeloblasts in AML-M2
por: Sharma, Sunita, et al.
Publicado: (2013)

Osteolytic Bone Lesions – A Rare Presentation of AML M6
por: Geetha, N., et al.
Publicado: (2015)

FLT3‐ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression
por: Soare, Dan‐Sebastian, et al.
Publicado: (2020)

Successful management of pulmonary hemorrhage and aspergillosis in a patient with acute myeloid leukemia (AML-M3)
por: Gunbatar, Hulya, et al.
Publicado: (2015)

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells
por: Zeng, Zhihong, et al.
Publicado: (2016)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

P1350: M2-LIKE MONOCYTE-DERIVED MACROPHAGES PROTECT AML CELL LINES AND PRIMARY AML CELLS AGAINST THERAPY-INDUCED APOPTOSIS
por: Miari, Katerina, et al.
Publicado: (2023)

Clinical and laboratory features of seven patients with acute myeloid leukemia (AML)-M2/M3 and elevated myeloblasts and abnormal promyelocytes
por: He, GanLin, et al.
Publicado: (2014)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

Spontaneous remission in three cases of AML M5 with NPM1 mutation
por: Camus, Vincent, et al.
Publicado: (2015)

The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
por: Nepstad, Ina, et al.
Publicado: (2020)

A Review of FLT3 Kinase Inhibitors in AML
por: Negotei, Cristina, et al.
Publicado: (2023)

Expression of DR4, DR5, FAS, Caspase-8 and, DDIAS Genes in AML Patients
por: Naghinezhad, Jalal, et al.
Publicado: (2023)

CALCRL Gene is a Suitable Prognostic Factor in AML/ETO(+) AML Patients
por: Wang, Rongrong, et al.
Publicado: (2022)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

Targeting AML through DR4 with a novel variant of rhTRAIL
por: Szegezdi, Eva, et al.
Publicado: (2011)

Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7
por: Kunimoto, Hiroyoshi, et al.
Publicado: (2020)

Divergent CD4(+) T-cell profiles are associated with anti-HLA alloimmunization status in platelet-transfused AML patients
por: Khelfa, Mehdi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_00njn9mcoco7bin9p7f9ob45b3